GGrantIndex
← Leaderboards

Gregory P Adams

Fox Chase Cancer Center

$4,024,285
Attributed
$4,024,285
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY200511
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$4,024,285 · 3

By mechanism

P50$1,955,622 · 1
R01$1,555,663 · 1
R21$513,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Fox Chase Cancer Center

Same institution · by research overlap

Others in their field

Top investigators on “Erbb2 Gene

Research focus

Erbb2 GeneAffinityIn VivoBaseCellsPropertyTumorAntibodiesMalignant NeoplasmsImmunodeficient MouseNeoplastic CellAntigensAntigen TargetingMutantBlood VesselsMouse ModelPublic Health Medicine (Field)Binding (Molecular Function)Solid NeoplasmEngineeringAffectBiodistributionNormal Tissue MorphologyTranslating

Grant awards (13)

Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$305,975
R01 · FY2011 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$315,438
R01 · FY2010 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,607
R01 · FY2009 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2009 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$733,901
P50 · FY2008 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,607
R01 · FY2008 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2008 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$899,748
P50 · FY2007 · CA · contact PI
Defining the Role of Affinity in Antibody-Based Tumor Targeting and Penetration$311,036
R01 · FY2007 · CA · contact PI
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors$171,000
R21 · FY2007 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$106,581
P50 · FY2006 · CA · contact PI
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$128,658
P50 · FY2005 · CA
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to$86,734
P50 · FY2004 · CA